Keros CSO granted 75,000 stock options

Lerner Lorena Raquel reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Lerner Lorena Raquel reported acquisition or exercise transactions in this Form 4 filing.

Keros Therapeutics Chief Scientific Officer Lorena Raquel Lerner received a grant of 75,000 employee stock options on February 24, 2026. These options were awarded at no cost as part of her compensation and increase her directly held derivative securities to 75,000.

One-fourth of the option grant will vest on February 24, 2027, with the remaining options vesting in twelve substantially equal quarterly installments after that date, so long as she continues to provide services to the company through each vesting date.

Insider Trade Summary

Grant/Award: 75,000 shares

Grant/Award 1 txn

Insider Lerner Lorena Raquel

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	75,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 75,000 contracts (Direct)

Footnotes (1)

1. F1. One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2027, and the remaining shares subject to the option shall vest in twelve substantially equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Keros Therapeutics (KROS) report for its CSO?

Keros Therapeutics reported that Chief Scientific Officer Lorena Raquel Lerner received a grant of 75,000 employee stock options. The options were awarded on February 24, 2026 as compensation and increased her directly held derivative securities position to 75,000 options in total.

How many stock options were granted to the Keros Therapeutics (KROS) CSO?

Lorena Raquel Lerner was granted 75,000 employee stock options. This single award brought her total directly held derivative securities to 75,000 options, reflecting a new equity-based compensation grant rather than an open-market purchase or sale of Keros Therapeutics common stock.

What is the vesting schedule for the 75,000 Keros Therapeutics (KROS) stock options?

One-fourth of the 75,000 options will vest on February 24, 2027. The remaining options will then vest in twelve substantially equal quarterly installments, provided Ms. Lerner continues to provide service to Keros Therapeutics through each applicable vesting date in the schedule.

Does the Keros Therapeutics (KROS) Form 4 show a stock purchase or sale?

The Form 4 shows an acquisition by grant, not a market trade. Lorena Raquel Lerner received 75,000 employee stock options as a compensation award, coded as a grant or other acquisition, with no reported open-market buying or selling of existing Keros Therapeutics shares.

Who is the reporting insider in the latest Keros Therapeutics (KROS) Form 4?

The reporting insider is Lorena Raquel Lerner, Chief Scientific Officer of Keros Therapeutics. She is an officer but not listed as a director or 10% shareholder, and this Form 4 reports her receipt of 75,000 employee stock options as a new derivative securities grant.

How does the new option grant affect the Keros Therapeutics (KROS) CSO’s holdings?

Following the grant, Lorena Raquel Lerner holds 75,000 derivative securities in the form of employee stock options. This reflects the full 75,000-option award reported, all held directly, and represents an increase in her potential future equity exposure to Keros Therapeutics shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lerner Lorena Raquel

(Last) (First) (Middle)

C/O KEROS THERAPEUTICS, INC.

1050 WALTHAM STREET, SUITE 302

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$15.52	02/24/2026		A		75,000		(1)	02/23/2036	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. One-fourth (1/4th) of the shares subject to the option shall vest on February 24, 2027, and the remaining shares subject to the option shall vest in twelve substantially equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.

	/s/ Esther Cho, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.